Vyvanse (Lisdexamfetamine): Clinical Overview
Vyvanse is FDA-approved for ADHD in patients ≥6 years old and moderate-to-severe binge eating disorder (BED) in adults, with standard dosing starting at 30 mg daily and titrating to 50-70 mg daily (maximum 70 mg/day). 1
Approved Indications
Vyvanse has two FDA-approved indications 1:
- ADHD: Adults and pediatric patients ≥6 years of age
- Moderate-to-severe BED: Adults only
Critical limitation: Vyvanse is NOT approved for weight loss, and use of sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events 1. Pediatric patients <6 years with ADHD experienced more long-term weight loss than older patients 1.
Dosing Recommendations
ADHD (Adults and Children ≥6 years)
- Initial dose: 30 mg every morning
- Titration: Increase by 10-20 mg weekly
- Target dose: 30-70 mg per day
- Maximum dose: 70 mg per day 1
Binge Eating Disorder (Adults)
- Initial dose: 30 mg every morning
- Titration: Increase by 20 mg weekly
- Target dose: 50-70 mg per day
- Maximum dose: 70 mg per day 1
Renal Impairment Adjustments
- Severe renal impairment: Maximum 50 mg/day
- End-stage renal disease (ESRD): Maximum 30 mg/day 1
Absolute Contraindications
Vyvanse is contraindicated in 1:
- Known hypersensitivity to amphetamine products or any ingredient in Vyvanse (anaphylaxis, Stevens-Johnson Syndrome, angioedema, urticaria reported)
- Current MAOI use or within 14 days of stopping MAOIs (including linezolid or IV methylene blue) due to hypertensive crisis risk
Critical Warnings and Precautions
Boxed Warning: Abuse, Misuse, and Addiction
Vyvanse has high potential for abuse and misuse leading to substance use disorder 1. Before prescribing:
- Assess each patient's risk for abuse, misuse, and addiction
- Educate patients/families about risks and proper storage
- Monitor throughout treatment for signs of abuse/misuse
- Misuse can result in overdose and death 1
Clinical advantage: Lisdexamfetamine is a prodrug requiring enzymatic conversion by red blood cell peptidases to active d-amphetamine, which may reduce abuse potential compared to immediate-release amphetamines 2, 3. The AAP guidelines specifically note Vyvanse as having "less abuse potential" and recommend it for adolescents at risk for diversion 2.
Cardiac Risks
Avoid use in patients with 1:
- Known structural cardiac abnormalities
- Cardiomyopathy
- Serious cardiac arrhythmia
- Coronary artery disease
- Other serious cardiac disease
Assess for cardiac disease before treatment 1. Sudden death has been reported in patients with structural cardiac abnormalities treated with CNS stimulants at recommended ADHD dosages 1.
Cardiovascular Monitoring
CNS stimulants cause 1:
- Blood pressure increase (mean 2-4 mmHg)
- Heart rate increase (mean 3-6 bpm)
- Monitor blood pressure and pulse in all patients
Psychiatric Risks
Screen before initiating treatment 1:
- Assess for risk factors for manic episodes (history of depression, family history of suicide/bipolar disorder/depression)
- Evaluate family history and patient for tics or Tourette's syndrome
Psychiatric adverse reactions 1:
- May exacerbate pre-existing psychosis
- May induce manic/mixed episodes in bipolar disorder
- New psychotic/manic symptoms occur in ~0.1% of stimulant-treated patients
- If new psychotic or manic symptoms occur, consider discontinuing Vyvanse
Growth Suppression in Pediatric Patients
Closely monitor height and weight in pediatric patients 1. Patients not growing or gaining weight as expected may need treatment interruption 1.
Peripheral Vasculopathy
Careful observation for digital changes is necessary 1. Signs/symptoms of peripheral vasculopathy (including Raynaud's phenomenon) warrant further clinical evaluation, potentially including rheumatology referral 1.
Serotonin Syndrome
Increased risk when co-administered with serotonergic agents (SSRIs, SNRIs, triptans) or during overdose 1. If it occurs, discontinue Vyvanse and initiate supportive treatment 1.
Common Adverse Effects
ADHD Patients (≥5% incidence, ≥2× placebo) 1:
- Decreased appetite/anorexia
- Insomnia
- Dry mouth
- Upper abdominal pain
- Irritability
- Anxiety
- Dizziness
- Decreased weight
- Nausea
- Vomiting
- Diarrhea
BED Patients (≥5% incidence, ≥2× placebo) 1:
- Dry mouth
- Insomnia
- Decreased appetite
- Increased heart rate
- Constipation
- Feeling jittery
- Anxiety
Most adverse events are mild-to-moderate in severity 4, 5.
Drug Interactions
pH-altering agents 1:
- Acidifying agents (decrease amphetamine levels): May require dose increase
- Alkalinizing agents (increase amphetamine levels): May require dose decrease
- Adjust Vyvanse dosage accordingly
MAOIs: Absolute contraindication 1
Monitoring Requirements
Before initiating treatment 1:
- Assess cardiac disease presence
- Screen for psychiatric risk factors (bipolar disorder, psychosis, family history)
- Evaluate for tics/Tourette's syndrome
- Assess abuse/misuse/addiction risk
During treatment 1:
- Blood pressure and pulse at each visit
- Height and weight in pediatric patients
- Signs/symptoms of abuse, misuse, addiction
- Prescription refill requests for diversion signs
- Digital changes (peripheral vasculopathy)
- Emergence/worsening of tics
- Psychiatric symptoms
Clinical Pearls
Pharmacokinetic advantage: Lisdexamfetamine provides approximately 12-hour duration of action with once-daily dosing 3, making it suitable for adolescents who need coverage while driving 2.
Adolescent considerations: The AAP guidelines specifically recommend Vyvanse for adolescents at risk for medication diversion because it is only activated after ingestion when metabolized by red blood cells to dexamphetamine, making extraction difficult 2.
Efficacy: Demonstrated significant reductions in ADHD-RS scores (approximately 27 points in children, 19 points in adults) 3 and sustained effectiveness up to 12 months 5.